Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells

Annals of Oncology

Volumn 19, Issue 11, 2008, Pages 1860-1869

  Esparis Ogando A ^a   Ocana A ^b   Rodriguez Barrueco R ^a   Ferreira, L ^a   Borges, J ^a   Pandiella, Atanasio ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

Breast cancer; IGF IR; Trastuzumab

Indexed keywords

DOCETAXEL; NVP AEW 541; PROTEIN KINASE B; PROTEIN P27; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNINDEXED SEQUENCE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; PYRIMIDINES; PYRROLES; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1;

EID: 54949138880     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn406     Document Type: Article

References (44)

1. Blume-Jensen P, Hunter T, Oncogenic kinase signalling. Nature 2001; 411: 355-365.
2. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
3. Nahta R, Yu D, Hung MC et al. Mechanism of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3: 269-280.
4. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
5. Nahta R, Esteva FJ. Trastuzumab: Triumphs and tribulations. Oncogene 2007; 26: 3637-3643.
6. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
7. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Mad 2001; 344: 783-792.
8. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006; 11(Suppl 1): 4-12.
9. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predict trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127.
10. Scaltriti M, Rojo F, Ocana A et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99: 628-638.
11. Lu Y, Zi X, Zhao Y et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93: 1852-1857.
12. Ibrahim YH, Yee D. Insulin-like growth factor-I and breast cancer therapy. Clin Cancer Res 2005; 11: 944s-950s.
13. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 2000; 5: 95-105.
14. Hankinson SE, Willett WC, Colditz GA et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393-1396.
15. Jerome L, Shiry L, Leyland-Jones B. Deregulation of the IGF axis in cancer: Epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003; 10: 561-578.
16. Carboni JM, Lee AV, Hadsell DL et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005; 65: 3781-3787.
17. Hartog H, Wesseling J, Boezen HM, van der Graaf WT. The insulin-like growth factor 1 receptor in cancer: Old focus, new future. Eur J Cancer 2007; 43: 1895-1904.
18. Haluska P, Shaw HM, Batzel GN et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13: 5834-5840.
19. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: Implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006; 66: 2391-2402.
20. Garcia-Echeverria C, Pearson MA, Marti A et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231-239.
21. Mitsiades CS, Mitsiades NS, McMullan CJ et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-230.
22. Scotlandi K, Manara MC, Nicoletti G et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005; 65: 3868-3876.
23. Tanno B, Mancini C, Vitali R et al. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res 2006; 12: 6772-6780.
24. Cabrera N, Díaz-Rodríguez E, Becker E et al. TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment. J Cell Biol 1996; 132: 427-436.
25. Esparís-Ogando A, Diaz-Rodriguez E, Montero JC et al. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol 2002; 22: 270-285.
26. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-1524.
27. Agus D, Akita R, Fox W et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2: 127-137.
28. Finn RS, Dering J, Ginther C et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105(3): 319-326.
29. Yuste L, Montero JC, Esparis-Ogando A, Pandiella A. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res 2005; 65: 6801-6810.
30. Carracedo A, Lorente M, Egia A et al. The stress-regulated protein p8 mediates cannabinold-induced apoptosis of tumor cells. Cancer Cell 2006; 9: 301-312.
31. Jerome L, Alami N, Belanger S et al. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res 2006; 66: 7245-7252.
32. Nahta R, Yuan LX, Deng B et al. Insulin-like growth factor-I receptor/ human epidermal growth factor receptor 2 heterodimerization contributes to trastuzurnab resistance of breast cancer cells. Cancer Res 2005; 65: 11118-11128.
33. Shin I, Yakes FM, Rojo F et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization, Nat Med 2002; 8: 1145-1152.
34. Weiss RH. p2(Waf1/Clp1) as a therapeutic target in breast and other cancers. Cancer Cell 2003; 4: 425-429.
35. Dupont J, Karas M, LeRoith D. The cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of Insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells. J Biol Chem 2003; 278: 37256-37264.
36. Tazzari PL, Tabellini G, Bortul R et al. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myelold leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 2007; 21(5): 886-896.
37. Butt AJ, Firth SMI, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and BcI-2 and potentates p53-Independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000; 275: 39174-39181.
38. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trasluzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 1800-1808.
39. Yakes FM, Chinratanalab W, Ritter CA et al. Herceptin-indured inhibition of phosphatidylinositol-3 kinase and Akt is required for antitiody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62: 4132-4141.
40. Lane HA, Beuvink I, Motoyama AB et al. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000; 20: 3210-3223.
41. Basmaciogullari S, Autiero M, Culerrier R et al, Mapping the CD4 binding domain of gp17, a glycoprotein secreted from seminal vesicles and breast carcinomas. Biochemistry 2000; 39: 5332-5340.
42. Caputo E, Manco G, Mandrich L, Guardiola J. A novel aspartyl proteinase from apocrine epithelia and breast tumors. J Biol Chem 2000; 275: 7935-7941.
43. Yoder BJ, Tso E, Skacel M et al. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res 2005; 11: 186-192.
44. Keppler D. Towards novel anti-cancer strategies based on cystatin function. Cancer Lett 2006; 235: 159-176.